GovChime
Notice ID: 24b4866a4010444d9731dbbada97a693Special Notice

Notice of Intent to Sole Source: NanoString Technologies

Archived on June 16, 2021. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM UTC−04:00
Posted
May 17, 2021
Notice type
Special Notice
Agency
Department of WarDepartment of the Army

Notice details

Office
W4PZ USA MED RSCH ACQUIS ACT
Place of performance
Frederick, MD, 21702
Last updated
Dec 4, 2025

Identifiers

Solicitation number
W81XWH21R0047
Notice ID
24b4866a4010444d9731dbbada97a693

Description

THIS IS A NOTICE OF INTENT TO AWARD A SOLE-SOURCE CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. The U.S. Army Medical Research Acquisition Activity (USAMRAA) intends to award a sole source Blanket Purchase Agreement (BPA, in accordance with IAW FAR 13.5, to NanoString Technologies, Inc. 530 Fairview Avenue N. Seattle, WA 98109-5553, as the sole manufacturer and only responsible source that can provide commercial and custom NanoString assays, panels, and required consumable reagents which are compatible with their proprietary nCounter Analysis System. Provisions and clauses in effect through Federal Acquisition Circular 2021-05 are incorporated. The U.S. Army Research Institute of Infectious Diseases (USAMRIID) Diagnostic Systems Division (DSD), requires the establishment of a Blanket Purchase Agreement (BPA) with NanoString Technologies, Inc. to provide Commercial Off-the-Shelf and custom assays, panels, and required consumable reagents which are compatible with their proprietary nCounter Analysis System. The custom assays, panels and consumable reagents include but are not limited to the following items: nCounter GX Custom CodeSet XT-GXA-P1CS-096 nCounter GX Custom CodeSet XT-GXA-P1CS-192 nCounter GX Custom CodeSet XT-GXA-P1CS-768 nCounter GX Custom CodeSet XT-GXA-P1CS-960 nCounter Custom CodeSet Plus CSP-192 nCounter Custom CodeSet Plus CSP-576 nCounter Human Immunology V2 CSO XT-CSO-HIM2-12 nCounter Mouse Immunology Kit V1 CSO XT-CSO-M1M1-12 nCounter Human PanCancer Pathways Panel CSO XT-CSO-PATH1-12 nCounter Human Inflammation V2 CSO XT-CSO-MIN2-12 nCounter Panel Plus PPL-192 nCounter Panel Plus PPL-576 nCounter Master Kit NAA-AKIT-192 The nCounter Analysis System is used to measure the abundance of specific genes and/or proteins in biological samples by labeling them with fluorescent barcodes and then counting them utilizing a digital imager. USAMRIIDs DSD currently utilizes the NanoString nCounter Analysis System to execute existing diagnostics, vaccines, and therapeutics research programs funded by the Defense Threat Reduction Agency and other sponsors. USAMRIID investigators have been developing research programs based on NanoStrings platform since FY2014. Moreover, USAMRIIDs DSD has ongoing, mission critical research projects for FY2021-2026 which rely on NanoStrings platform. For scientific and programmatic consistency, the Government must complete on-going multi-year research projects using the NanoString nCounter Analysis System and its associated reagents. The intended acquisition will be classified under North American Industry Classification System (NAICS) 325413, In-Vitro Diagnostic Substance Manufacturing, with a Small Business Size Standard of 1,250 employees. This announcement fulfills the synopsis requirements under FAR 5.102(a)(3) and 5.203(a)(1). USAMRAA intends to release a solicitation no sooner than 15 days after publishing this synopsis. This Special Notice of Intent is not a request for competitive quotes. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no meaningful, written submissions are received by the date listed below, which reflects at least ten (10) days after the publication of this notice, the solicitation will be issued as a sole source requirement to NanoString Technologies, Inc. All questions and responses concerning this notice shall be emailed to Rebecca Wisner at rebecca.c.wisner.civ@mail.mil. Interested concerns must identify their capability in writing to the above e-mail address no later than 10:00 AM Eastern Daylight Time (EDT), 01 June 2021. No phone calls accepted.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:W81XWH21R0047
  1. Special NoticeCurrentMay 17, 2021

    Notice of Intent to Sole Source: NanoString Technologies

    Notice 24b4866a4010444d9731dbbada97a693 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This innovation from scientists at Los Alamos National Laboratory is a significant improvement on a gold standard protein purification method that gently captures and releases antibodies using mild pH changes, making antibody purification safer, more efficient, and less damaging. The Challenge: Purifying antibodies — vital tools in medicine and research — typically relies on a protein called Protein G that latches onto them. However, getting the antibodies back off this molecular “magnet” requires very acidic conditions, which can damage both the antibodies and Protein G itself. This harsh process risks ruining expensive materials and reducing the effectiveness of critical therapies and tests. Problems Solved: Researchers engineered a pH-switchable version of Protein G that uses gentle changes in acidity (pH) to control when it releases antibodies, it now binds antibodies at a mildly acidic pH and releases at a mildly basic pH — eliminating the need for harsh chemicals. This innovation protects sensitive proteins, improves efficiency, lowers costs, and opens the door for safer, greener, and more effective antibody purification in both labs and industry. Key Advantages: Gentle elution conditions: Antibodies are released at a mild pH (~8.2) instead of harsh acidic conditions (~2.7), reducing damage to both the antibodies and the protein itself. Improved antibody stability and yield: Preserving antibody structure increases reliability and effectiveness, which is especially critical for therapeutic and diagnostic use. Switchable binding mechanism: pH-sensitive histidine residues allow for a controlled "on/off" switch based on pH, improving process control and reproducibility. Cost-effective and scalable: Reduces loss of expensive antibodies and minimizes the need for post-purification repair or replacement, saving money in industrial applications. Market Applications: Biopharmaceuticals Life Sciences Research Bioprocessing and Manufacturing Tools Veterinary and Agricultural Biotech Development Status: TRL 4 US Provisional / Patent No. 10,954,275 LA-UR-25-29451 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search
65%
Special Notice12/05/2025
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers.
51%
Combined Synopsis11/18/2026
DESCRIPTION This RFI is solely for information and planning purposes and does not constitute a solicitation or obligation on the part of the Government. Per FAR 15.201(e), responses to this notice are not considered offers, shall not be used as a proposal, and cannot be accepted by the Government to form a binding contract. Neither unsolicited proposals nor any other kinds of offers will be considered in response to this notice. No evaluation letters and/or results will be issued to the respondents; however, the Government does reserve the right to contact any respondent and/or respondent reference to obtain additional information. At this time, no solicitation exists; therefore, please do not request a copy of the solicitation. Any resulting procurement action will be the subject of a separate, future announcement. The information is provided for discussion purposes and any potential strategy for this acquisition may change prior to any solicitation release. The acquisition strategy, evaluation methodology, contract type, and any other acquisition decisions are to be determined. Background. The offeror shall provide to the Veterans Affairs Medical Health Care System at Baltimore VAMC all reagents and supplies for flow cytometry testing in the Hematology section of Pathology and Laboratory Medicine Service. The reagents/supplies will be used for CD4/CD8 count testing and the phenotyping of white blood cells in the leukemia and lymphoma assay using the Becton Dickinson FACSLyric. QC material and calibration material are used for the detection of voltages and spectral overlap to monitor optimal cytometer settings, checks, and track the daily performance. Performance Period: 12/03/2026 to 12/02/2027 Quantities are estimates: Item # Description Qty 643774 Anti-Kappa FITC TB28-2 ASR 4 642924 Anti-Lambda PE 1-55-2 ASR 4 341103 CD19 PE-Cy7 SJ25C1 ASR 4 340922 CD10 APC HI10a ASR 4 641405 CD20 APC-H7 L27 ASR 4 646852 CD38 V450 ASR 3 647450 CD45 V500-C ASR 4 663985 CD5 (L17F12) BV605 ASR 4 340918 FMC7 FITC ASR 4 340997 CD103 PE Ber-ACT8 ASR 2 659116 CD23 APC-R700 (EBVCS-5) ASR 3 655112 CD11c V450 ASR 3 340706 CD57 FITC HNK-1 ASR 3 340948 CD3 PerCP-Cy5.5 SK7 ASR 3 335804 CD2 PE-Cy7 L303.1 ASR 3 562660 Hu CD25 BV605 2A3 100Tst 3 659115 CD7 APC-R700 (M-T701) ASR 3 641409 CD8 APC-H7 SK1 ASR 3 651850 CD4 V450 (SK3) ASR 3 340688 Anti-HLA-DR FITC L243 (G46-6) ASR 3 644386 CD64 PE 10.1 ASR 3 338432 CD13 PE-Cy7 L138 ASR 3 340667 CD34 APC 8G12 ASR 3 659113 CD33 APC-R700 (P67-6) ASR 3 643077 CD14 APC-H7 MphiP9 ASR 3 663803 CD117 (104D2) BV605 ASR 3 657887 CD56 APC-R700 NCAM16.2 ASR 3 563826 Hu Alp Bta TCR APC T10B9.1A-31 100Tst 2 341635 CD30 PE Ber-H83 ASR 2 341097 CD138 PerCP-Cy5.5 MI15 ASR 2 655019 CD27 APC (L128) ASR 2 665134 CD81 (JS-81) BV605 ASR 2 656311 CD22 PerCP-Cy5.5 (S-HCL-1) ASR 3 663994 CD123 (9F5) APC-R700 ASR 2 649455 CD26 PE (L272) ASR 2 655434 TCR gamma/delta-1 PE-Cy7 (11F2) ASR 2 340655 Anti-MPO FITC 5B8 ASR 2 347209 Anti-TdT PE E17-1519 ASR 2 659114 CD34 APC-R700 (8G12) ASR 3 664538 CD22 (S-HCL-1) PE-Cy7 ASR 2 340653 CD79a APC HM47 ASR 2 341641 CD1a PE SK9 ASR 2 663196 CD158a (HP-3E4) PE ASR 2 663990 CD56 (NCAM16.2) BV605 ASR 2 644490 CD 16 V450 3G8 ASR 2 562361 Hu CD94 PerCP-CY5.5 HP-3D9 100Tst 2 562124 Hu CD200 PerCP-Cy5.5 MRC OX-104 50Tst 3 656152 CD36 FITC CLB-IVC7 ASR 2 562371 Hu CD 15 PE W6D3 100Tst 2 340936 CD11b APC D12 ASR 2 347213 CD34 PerCP-Cy5.5 8G12 ASR 2 340715 CD61 FITC RUU-PL7F12 ASR 2 340946 Glycophorin A PE GAR-2(HIR2) ASR 2 644490 CD 16 V450 3G8 ASR 2 662414 CST beads 150T IVD 2 342003 BD FACSFlow Sheath Fluid 20L 20 349202 BD FACS Lysing Solution 10X 100ML IVD 2 559925 7-AAD Staining Solution 2mL 3 563794 Brilliant Stain Buffer 5ml 6 554656 Stain Buffer FBS 500mL 20 552843 Ms Ig Kpa Comp Bead Set 6mL 1 555899 Lysing Buffer 10X Concentrate 100mL 8 340345 BD FACS Clean Solution 5L 1 562776 Ms CD140A PE APA5 50ug 3 340499 Multitest CD3/CD8/CD45/CD4 50 Tests IVD 30 662961 BD FC Beads 7-Color Kit (US-IVD) 1 349705 Multi-Check CD4 Low Ctrl 5X2.5mL US-IVD 6 349702 Multi-Check Control 5X2.5mL US-IVD 6 661624 BD FC Beads V500-C 1 661623 BD FC Beads V450 1 661626 BD FC Beads BV605 1 661621 BD FC Beads APC-H7 1 661625 BD FC Beads APC-R700 1 RESPONSES: Please include descriptive literature demonstrating the product meets or exceeds the brand name product specified above. Please provide any product solution or configuration so long as they are equivalent to the brand name product. Responses can include any additional product that may be beneficial. These items must be clearly identified by brand name and part number. PLEASE PROVIDE THE FOLLOWING ADDITIONAL INFORMATION: Full name and address of company DUNS number/ CAGE Code/ SAM UEI Business Size Manufacturer or Distributor If distributor, provide full name, business size, and address of manufacturer. Country of Origin designation for all products. Technical Literature that clearly shows product(s) are equivalent. Any additional product solution or configuration that would be beneficial to the functionality of the product line identified. Authorized Distributor Letter Certified by OEM with a current date. Although not required, vendors responding to this Sources Sought may also submit a Capabilities Statement.
51%
Market Research11/12/2026
46%
AwardedOpen
Effective Date: 01/15/2026 Revision: 03 Description This is a combined synopsis/solicitation for commercial products and commercial services prepared in accordance with the format Revolutionary FAR Overhaul (RFO) in Federal Acquisition Regulation (FAR) subpart 12.202, Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial Services, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation document will not be issued. This solicitation is issued as an RFQ. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01 This solicitation is unrestricted, Full and Open competition. The associated North American Industrial Classification System (NAICS) code for this procurement is 325413 with a small business size standard of 1250 employees. The FSC/PSC is 6550. The Network Contracting Office 5 is seeking to purchase BD FACSLyric Flow Cytometry Reagents/Supplies for the Baltimore VAMC located at 10 N Greene Street, Baltimore, MD 21201. All interested companies shall provide quotations for the following: See Attachment labeled Line Item Template Note: All quantities are estimates Statement of Work BD FACSLyric Flow Cytometry Reagents/Supplies Introduction: Technology: Flow cytometry is a technology that simultaneously measures and then analyzes multiple physical characteristics of single particles, usually cells, as they flow in a fluid stream through a beam of light. The parameters measured include the particle size, granularity or internal complexity, and fluorescence intensity. An optical-to-electronic coupling system determines these characteristics by recording how the cell or particle scatters incident laser light and emits fluorescence. These scatter and fluorescence signals, detected by the instrument, provide information about the cell s size, internal complexity, and relative fluorescence intensity. BD Multisets reagents employ fluorescence triggering, allowing direct fluorescence gating of the lymphocyte population to reduce contamination of lyse-resistant or nucleated red blood cells in the gate. To prepare for flow analysis, a patient s whole blood is added to the reagent, and the fluorochrome-labeled antibodies in the reagent bind specifically to the leucocyte s surface antigens. During acquisition, the stained cells travel past the laser beam and scatter the laser light. The staining pattern of each population, combined with forward-scattered light (FSC) and side-scattered light (SSC) data, can be used to identify which cell populations are present in the patient sample. Photodetectors (Photo iodide & Photomultiplier tubes/PMT) convert the light signals to electronic signals, which are then converted into digital channel numbers for display on a data plot. Scope of work: General: The offeror shall provide to the Veterans Affairs Medical Health Care System at Baltimore VAMC all reagents and supplies for flow cytometry testing in the Hematology section of Pathology and Laboratory Medicine Service. The reagents/supplies will be used for CD4/CD8 count testing and the phenotyping of white blood cells in the leukemia and lymphoma assay using the FACSLyric. QC material and calibration material are used for the detection of voltages and spectral overlap to monitor optimal cytometer settings, checks, and track the daily performance. Term of Agreement: The contract term is for 1 year. Performance Period: 12/03/2026 to 12/02/2027 Reagents: Monoclonal Antibodies for Leukemia and lymphoma diagnostic. The quantity of reagents in this list was based on the data collected from the volume of patients received in 2024 and 2025. The leukemia population was around 300 patients, and the CD4/CD8 T-cell helper testing request was around 3000 patients Place of Performance/Place of Delivery Address: 10 N Greene Street, Baltimore, MD 21201. Country: UNITED STATES The full text of FAR provisions or clauses may be accessed electronically at https://www.acquisition.gov/browse/index/far. https://www.va.gov/oal/library/vaar/ The following solicitation provisions and clause apply to this acquisition: FAR 52.212-1, Instructions to Offerors Commercial Products and Commercial Services Solicitation Provisions (Incorporated by Reference) Provision Title Date FAR 52.204-7 System for Award Management Jan 2025 FAR 52.204-16 Commercial and Government Entity Code Reporting Aug 2020 FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment Nov 2021 FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation Jan 2025 FAR 52.212-1 Instructions to Offerors-Commercial Products and Commercial Services Sep 2023 FAR 52.212-2 Evaluation-Commercial Products and Commercial Services Nov 2021 FAR 52.212-3 Offeror Representations and Certifications-Commercial Products and Commercial Services Jan 2025 FAR 52.225-2 Buy American Certificate Feb 2021 VAAR 852.211-73 Brand Name or Equal Feb 2023 Complete Attachment Line Item Template columns K, L N, O, BZ, CF and CH. Do not alter the template beyond those columns. Provide documentation that firm is either the manufacturer or an authorized distributor. All products must be able to work in the Becton Dickinson FACSLyric Flow Cytometry analyzer. All quotes shall be sent to alison.klein@va.gov. FAR 52.212-2 Evaluation-Commercial Products and Commercial Services: In accordance with RFO FAR 12.201-1 and FAR 12.201-2 when appropriate, the contracting officer may (1) Insert the provision at 52.212-2, Evaluation-Commercial Products and Commercial Services, in solicitations for commercial products or commercial services. The following are the decision factors: Evaluation Criteria: FACTOR (1) Past Performance Acceptable - The company s performance was satisfactory, and you would consider doing business with them again. There were minor performance problems, which were satisfactorily corrected. Unacceptable - The company s performance was entirely unsatisfactory, and you would not do business with them again under any circumstances. There were serious performance issues with the contractor, for which the contractor s corrective actions were ineffective. Contractors must be rated as Acceptable for Past Performance to be evaluated for Technical Capability and Price. FACTOR (2): Technical Capability Technical capability will be determined solely on the content and merit of the information submitted in response to this request. Therefore, it is incumbent on the interested party to provide sufficient documentation for the Government to make an adequate technical assessment of the contractor's capabilities. Acceptable - The contractor s technical approach meets and /or exceeds the requirements set forth in the SOW. Unacceptable - The contractor s capability does not meet one or more of the specifications set forth in the SOW. Contractors must be rated as Acceptable for Past Performance and Acceptable for Technical Capability to be evaluated for Price. FACTOR (3): Price The Price Quote shall include all price elements applicable to the proposed effort. Basis for Award: To be eligible for an award, an Offeror s quote must be determined acceptable past performance and technical capability. The Government shall evaluate quotes and an award will be made to the responsible Offeror whose acceptable offer meets all past performance, technical capability, and price related factors. Offerors must complete annual representations and certifications electronically via the System for Award Management (SAM) website located at https://sam.gov/. FAR 52.212-4, Contract Terms and Conditions Commercial Products and Commercial Services NOV 2023. The full text of FAR provisions or clauses may be accessed electronically at https://www.acquisition.gov/browse/index/far. https://www.va.gov/oal/library/vaar/ 52.222-90 Addressing DEI Discrimination by Federal Contractors. As prescribed in 22.2203, insert the following clause: Addressing DEI Discrimination by Federal Contractors (Deviation DATE) (a) Definitions. As used in this clause Program participation means membership or participation in, or access or admission to: training, mentoring, or leadership development programs; educational opportunities; clubs; associations; or similar opportunities that are sponsored or established by the contractor or subcontractor. Racially discriminatory diversity, equity, and inclusion (DEI) activities means disparate treatment based on race or ethnicity in the recruitment, employment (e.g., hiring, promotions), contracting (e.g., vendor agreements), program participation, or allocation or deployment of an entity's resources. (b) In connection with the performance of work under this contract, the Contractor agrees as follows: (1) The Contractor will not engage in any racially discriminatory DEI activities; (2) The Contractor will furnish all information and reports, including providing access to books, records, and accounts, as required by the Contracting Officer, for purposes of ascertaining compliance with this clause; (3) In the event of the Contractor's or a subcontractor's noncompliance with this clause, this contract may be canceled, terminated, or suspended in whole or in part, and the Contractor or subcontractor may be declared ineligible for further Government contracts; (4) The Contractor will report any subcontractor's known or reasonably knowable conduct that may violate this clause to the Contracting Officer and take any appropriate remedial actions directed by the Contracting Officer; and (5) The Contractor will inform the Contracting Officer if a subcontractor sues the Contractor and the suit puts at issue, in any way, the validity of this clause. (6) The Contractor recognizes that compliance with the requirements of this clause are material to the Government's payment decisions for purposes of 31 U.S.C. 3729(b)(4). (c) The Contractor must include the substance of this clause, including this paragraph (c), in subcontracts at any tier, including those for commercial products and commercial services, except those where the place of delivery or performance is outside the United States. (End of clause) Contract Clauses (Incorporated by Reference) Clause Title Date FAR 52.203-19 Prohibition on Requiring Certain Internal Confidentiality Agreements or Statements Jan 2025 FAR 52.204-13 System for Award Management Maintenance Oct 2018 FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment Jan 2025 52.203-17 Contractor Employee Whistleblower Rights and Requirement To Inform Employees of Whistleblower Rights Jun 2020 52.204-10 Reporting Executive Compensation and First-Tier Subcontract Awards Jun 2020 52.204-27 Prohibition on a ByteDance Covered Application Jun 2023 52.219-28 Post-Award Small Business Program Representation Feb 2024 52.222-3 Convict Labor Jun 2003 52.222-19 Child Labor-Cooperation with Authorities and Remedies Feb 2024 52.222-21 Prohibition of Segregated Facilities Apr 2015 52.222-26 Equal Opportunity Sep 2016 52.222-36 Equal Opportunity for Workers with Disabilities Jun 2020 52.222-50 Combating Trafficking in Persons Nov 2021 52.223-18 Encouraging Contractor Policies to Ban Text Messaging While Driving Jun 2020 52.225-1 Buy American -Supplies Oct 2022 52.225-13 Restrictions on Certain Foreign Purchases Feb 2021 52.232-33 Payment by Electronic Funds Transfer-System for Award Management Oct 2018 To facilitate the award process, all quotes must include a statement regarding the terms and conditions herein as follows: "The terms and conditions in the solicitation are acceptable to be included in the award document without modification, deletion, or addition." OR "The terms and conditions in the solicitation are acceptable to be included in the award document with the exception, deletion, or addition of the following:" Quoters shall list exception(s) and rationale for the exception(s), if any. Submission of your response shall be received not later than 11/27/2026 at 12pm ET. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to the Point of Contact listed below. Point of Contact Alison Klein at alison.klein@va.gov
46%
Combined Synopsis11/27/2026

Additional Details

Solicitation Number

W81XWH21R0047

Archive Date

Jun 16, 2021

Office Address

FORT DETRICK, MD, 21702-5014